TWST FY2025 SEC EDGAR DEF 14A #164 of 168 in industry

Twist Bioscience Corp CEO pay ratio

The CEO earned $376K in FY2025 against median worker pay of $188,208 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-01-06
Industry
Chemicals & Pharmaceuticals
Industry rank
#164/168

Data updated August 2026

Subscribe to Twist Bioscience Corp CEO pay filing updates (RSS)

CEO-to-worker pay ratio
2:1
Below Average (Scale: 0–1000:1)
CEO pay
$376K
Median worker
$188,208

Answer first

Twist Bioscience Corp's FY2025 CEO total of $376K ranks #1293 of 1,423 complete filings; its 2:1 pay ratio ranks #1401. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $188,208. Industry placement uses the FY2025 SIC-28 peer cohort (# 164 of 168, 3rd percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1293
$376K of 1,423 FY2025
Ratio rank
#1401
2:1 of 1,423
Industry pct
3rd
among the lower quartile of industry peers by pay ratio

How Twist Bioscience Corp ranks nationally

Twist Bioscience Corp CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$376,416 9th percentile higher than 9% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Twist Bioscience Corp vs. Chemicals & Pharmaceuticals peers

CEO total pay ($376K) against pay ratio (2:1) for Twist Bioscience Corp (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02798065.35596130.68394195.911192261.30:111.0:122.0:133.0:144.0:1CEO total payPay ratio (CEO : median worker)Twist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpVanda Pharmaceuticals Inc., CEO total pay: 3851468 · Pay ratio (CEO : median worker): 1:1Vanda Pharmaceuticals Inc.Summit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.Spyre Therapeutics, Inc., CEO total pay: 437242 · Pay ratio (CEO : median worker): 1:1Spyre Therapeutics, Inc.Zai Lab Ltd, CEO total pay: 10677221 · Pay ratio (CEO : median worker): 1:1Zai Lab LtdVera Therapeutics, Inc., CEO total pay: 6986410 · Pay ratio (CEO : median worker): 3:1Vera Therapeutics, Inc.
Twist Bioscience Corp vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Twist Bioscience Corp's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Twist Bioscience Corp

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
2:1
FY2025
vs prior FY
-4:1
from FY2024 6:1
CEO $ YoY
-70%
$376K latest
Filings shown
4
FY2022–2025
Twist Bioscience Corp CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $1.6M - $174,809 9:1 -
2023 $866K -45% $123,646 7:1 -2:1
2024 $1.2M +44% $208,280 6:1 -1:1
2025 $376K -70% $188,208 2:1 -4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1581280, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
2:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$376K
Companies in Industry
168
vs. Industry Median
Below
#164 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Twist Bioscience Corp: near-parity Item 402(u) ratio

Twist Bioscience Corp's FY2025 ratio 2:1 ranks #164 of 168 Chemicals & Pharmaceuticals filers (3rd percentile). the CEO earned 2× the median employee ($188,208) in FY2025.

At $188,208 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.

CEO Total Pay

$376K

FY2025 Summary Compensation, below median

Pay Ratio

2:1

Below typical

Twist Bioscience Corp in the lower Chemicals & Pharmaceuticals third

Twist Bioscience Corp's FY2025 ratio 2:1 ranks #164 of 168 Chemicals & Pharmaceuticals filers (3rd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Twist Bioscience Corp's $376K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1293 and ratio rank #1401 split - treat 2:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$376K
Median Employee Pay
$188,208
Pay Ratio
2:1
Filing Date
2026-01-06

Company Info

Ticker
TWST
CIK
1581280
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1581280, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Twist Bioscience Corp's FY2025 ratio 2:1 ranks #164 of 168 Chemicals & Pharmaceuticals filers (3rd percentile).

Read with Twist Bioscience Corp

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.

Five Point Holdings, LLC · MICRO

ABS(ceo_total_comp) peer at $373K (Δ $3K lighter vs Twist Bioscience Corp); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Cincinnati Financial Corp · MICRO

ABS(ceo_total_comp) peer at $385K (Δ $8K heavier vs Twist Bioscience Corp); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Markel Group Inc. · MICRO

ABS(ceo_total_comp) peer at $364K (Δ $13K lighter vs Twist Bioscience Corp); FLOOR · HIGH-MED vs this page's FLOOR · MICRO · ELITE-MED.
BrightSpire Capital, Inc. · MICRO

ABS(ceo_total_comp) peer at $363K (Δ $13K lighter vs Twist Bioscience Corp); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Vanda Pharmaceuticals Inc. (SIC 28 pole)

Vanda Pharmaceuticals Inc. stamps PARITY · MID$ nearest in-SIC by ABS(pay_ratio) to Twist Bioscience Corp's FLOOR filing.
National dual ranks · #1293/#1401

Twist Bioscience Corp's FY2025 package sits #1293 by CEO dollars and #1401 by ratio under MICRO · FLOOR.
Ratio primer · FLOOR

Twist Bioscience Corp's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Twist Bioscience Corp (CIK 1581280), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.